Emergent BioSolutions EBS
NYSE EBS
$6.24 +0.01 (+0.16%)
As of: Oct 23, 2026 · 3:59 PM EDT

Emergent BioSolutions (EBS) Non Operating Investment Income (2023 - 2026)

Updated

Emergent BioSolutions (EBS) reported Non Operating Investment Income of -$10.7 million for Q2 2026.

Analysis

Emergent BioSolutions (EBS) Non Operating Investment Income (2023 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Emergent BioSolutions' Non Operating Investment Income came in at $1.5 million, down 97.1% year-over-year; for FY2024, it was $24.3 million, down 67.3% from FY2023.

  • By year, Non Operating Investment Income came in at $74.2 million in FY2023.
  • The Q2 2026 figure ranks as the lowest quarterly Non Operating Investment Income since Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Op. Investment Inc. (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn -
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn -
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn -
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn -
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn -
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn -
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn -
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn -
10 Emergent BioSolutions 321.73 Mn -429.17 Mn 137.20 Mn -10.70 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -10.70 Mn
Dec 31, 2025 12.20 Mn
Mar 31, 2025 -12.20 Mn
Sep 30, 2024 64.30 Mn
Jun 30, 2024 -40.00 Mn
Sep 30, 2023 -700,000.00
Jun 30, 2023 74.90 Mn
API Access

Emergent BioSolutions Non Operating Investment Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=EBS&period=max&api_key=YOUR_API_KEY